Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (22619)	6/23/1998 10:58:00 AM
From: Phil Cressman	Respond to of 32384

Will LGND keep and develop these molecules to market or are we likely to see a joint venture with a major pharma. Would likely cost a lot of money to take these compounds thru to approval/use and marketing. Maybe LGND will keep dilution in mind this time around although selling stock at $17+ helps us all in extablishing a fairer, IMO, price for LGND stock.

To: Flagrante Delictu who wrote (22619)	6/23/1998 11:18:00 AM
From: Henry Niman	Respond to of 32384

Bernie, I tend to classify the platforms based on the target, so I would call the polypeptide hormone mimics a third area because they target the extracellular domain of the receptor. However, since they act at the front end of the STAT pathway, I think that LGND still considers them as part of the STAT technology. Today's announcement is for another group of compounds that target IRs, so I wouldn't put them in a separate category. In fact they really extend LGND's designer estrogen approach to progestins (and such an approach would have applications for other IRs). Today's news shows just how powerful LGND's screening assay, and it opens up another new set of targets and markets. The market for HRT and birth control is of course very large, and today's announcement puts LGND at the front of another race to develop blockbuster drugs.